Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Knight SHIFT: Timing of Immunotherapy in Solid Tumors
NCT07405086Phase 4Recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in solid tumor (2 cohorts), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Progression-Free Survival up to 2 years. Started Apr 2026; status: recruiting.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07405086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07405086.